Sandbox:MGS

Waldenström's macroglobulinemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Waldenström's macroglobulinemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Bone Marrow Aspiration and Biopsy
Electrophoresis and Immunofixation
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Sandbox:MGS On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Sandbox:MGS All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Sandbox:MGS
CDC on Sandbox:MGS
Sandbox:MGS in the news
Blogs on Sandbox:MGS
Directions to Hospitals Treating Waldenström's macroglobulinemia
Risk calculators and risk factors for Sandbox:MGS

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mirdula Sharma, MBBS [2]

References

Treatment regimen	Drugs	Side effects
CHOP-R regimen	Cyclophosphamide Doxorubicin Vincristine Prednisone Rituximab	Nausea Alopecia Granulocytopenia
Ibrutinib	Ibrutinib	Fatigue Cytopenia
Rituximab	*Rituximab	*Infusion related reaction Infections
FR regimen	*Fludarabine Rituximab	*Neutropenia (63%) Thrombocytopenia Pneumonia
BDR regimen	*Bortezomib Dexamethasone Rituximab	*Peripheral Neuropathy - reversible in 61% of patients
DRC regimen	*Dexamethasone Rituximab Cyclophosphamide	*Neutropenia
CR regimen	*Cladribine Rituximab	*Anemia Neurological symptoms Symptomatic cryoglobulinemia Thrombocytopenia